Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
rifampicin, Quantity: 150 mg
Alphapharm Pty Ltd
Capsule, hard
Excipient Ingredients: ascorbic acid; magnesium stearate; iron oxide red; colloidal anhydrous silica; purified water; lactose monohydrate; brilliant blue FCF; purified talc; iron oxide yellow; erythrosine; Gelatin; sodium lauryl sulfate; titanium dioxide
Oral
10, 100
(S4) Prescription Only Medicine
INDICATIONS AS AT 5 DECEMBER 2001 : Tuberculosis. In the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other antituberculosis drug. Leprosy - In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment. - As an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs. - As an alternative drug in all those patients having true drug allergy to the more commonly used anti-leprosy drugs.,Meningococcal Disease Prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections).,Haemophilus Influenzae Prophylaxis of household contacts of patients with Haemophilus influenzae type B.,Buruli Ulcer For the treatment of Myc
Visual Identification: Size 3 hard gelatin capsule, maroon body with black cap.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
1994-03-10
RIMYCIN R i m y c i n CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. WHY AM I USING RIMYCIN? RIMYCIN contains the active ingredient rifampicin. RIMYCIN is an antibiotic taken with other medicines to treat tuberculosis, leprosy and mycobacterium ulcerans (Buruli ulcer). It is also taken to prevent meningococcal disease and infections caused by Haemophilus Influenza Type B. For more information, see Section 1. Why am I using RIMYCIN? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE I TAKE RIMYCIN? Do not take RIMYCIN if you have ever had an allergic reaction to RIMYCIN or any of the ingredients listed at the end of the CMI. Do not take RIMYCIN if you have jaundice. Do not take RIMYCIN if you are taking saquinavir or ritonavir. These are medicines used to treat AIDS and HIV. TALK TO YOUR DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE BREASTFEEDING OR PLANNING TO BREASTFEED. For more information, see Section 2. What should I know before I take RIMYCIN? in the full CMI. 3. WHAT IF I AM TAKING OTHER MEDICINES? Some medicines may interfere with RIMYCIN and affect how it works. A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI. 4. HOW DO I TAKE RIMYCIN? Follow the instructions provided when RIMYCIN was prescribed, including the number of days it should be taken. More instructions can be found in Section 4. How do I take RIMYCIN? in the full CMI. 5. WHAT SHOULD I KNOW WHILE USING RIMYCIN? THINGS YOU SHOULD DO • Remind any doctor, dentist, surgeon, or pharmacist you visit that you are taking RIMYCIN. • You should see your doctor monthly for a check-up. • Continue taking RIMYCIN exactly as prescribed by your doctor. • If you have a blood or urine test, tell your doctor you are taking RIMYCIN. • If you are about to be started on a new medicine, including oral contracep Read the complete document
AUSTRALIAN PRODUCT INFORMATION RIMYCIN _rifampicin capsules _ 1 NAME OF THE MEDICINE Rifampicin 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each RIMYCIN capsule contains 150 mg or 300 mg of rifampicin as the active ingredient. Excipients with known effect: galactose, lactose and sulfites. For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM RIMYCIN 150 capsules are a size 3 hard gelatin capsule, maroon body with black cap. RIMYCIN 300 capsules are a size 1 hard gelatin capsule with maroon body and cap. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS TUBERCULOSIS In the initial treatment and in retreatment of patients with tuberculosis, rifampicin must be used in conjunction with at least one other anti-tuberculosis drug. LEPROSY • In the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the non-infectious state which may be expected to occur in three to four months of treatment • As an alternative drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other anti-leprosy drugs • As an alternative drug in all those patients having true drug allergy to the more commonly used anti- leprosy drugs MENINGOCOCCAL DISEASE Prophylaxis of meningococcal disease in close contacts of known cases and in carriers (rifampicin is not indicated for the treatment of meningococcal infections). HAEMOPHILUS INFLUENZAE Prophylaxis of household contacts of patients with _Haemophilus influenzae_ type B. BURULI ULCER For the treatment of Mycobacterium ulcerans infections (Buruli ulcer). Rifampicin must be used in combination with another anti-Mycobacterium ulcerans antibiotic. RIMYCIN – PRODUCT INFORMATION 2 4.2 DOSE AND METHOD OF ADMINISTRATION It is recommended that rifampicin be administered once daily, either 30 minutes before or two hours after a meal. PULMONARY TUBERCULOSIS Adults: 600 mg in a single daily administration. Children: 10 to 20 mg/kg, not to exceed 600 mg/day. LEPROSY Adu Read the complete document